Cancer immunotherapy

References

• Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; In press http://dx.doi.org/10.1007/s00262-011-1028-0; PMID: 21644036
   PubMed Web of Science ®Google Scholar
• Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335 - 45; http://dx.doi.org/10.1158/0008-5472.CAN-09-3767; PMID: 20484028
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49 - 59; http://dx.doi.org/10.1007/s00262-008-0523-4; PMID: 18446337
   PubMed Web of Science ®Google Scholar
• Mundy-Bosse BL, Thornton LM, Yang HC, Andersen BL, Carson WE. Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol 2011; 270:80 - 7; http://dx.doi.org/10.1016/j.cellimm.2011.04.003; PMID: 21600570
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101:10697 702; http://dx.doi.org/10.1073/pnas.0403572101; PMID: 15252201
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001; 166:6012 - 8; PMID: 11342617
   PubMed Web of Science ®Google Scholar
• Taraban VY, Martin S, Attfield KE, Glennie MJ, Elliott T, Elewaut D, et al. Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol 2008; 180:4615 - 20
   PubMed Web of Science ®Google Scholar
• Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, et al. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 2011; 187:708 - 17; http://dx.doi.org/10.4049/jimmunol.1100502; PMID: 21670315
   PubMed Web of Science ®Google Scholar
• Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 2009; 182:1818 - 28; http://dx.doi.org/10.4049/jimmunol.0802430; PMID: 19201833
   PubMed Web of Science ®Google Scholar
• Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer 2011; In press http://dx.doi.org/10.1002/ijc.26411; PMID: 21898392
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102:9571 - 6; http://dx.doi.org/10.1073/pnas.0503726102; PMID: 15980149
   PubMed Web of Science ®Google Scholar
• Perret R, Ronchese F. Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?. Tissue Antigens 2008; 72:187 - 94; http://dx.doi.org/10.1111/j.1399-0039.2008.01088.x; PMID: 18627571
   PubMed Web of Science ®Google Scholar
• Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008; 180:3627 - 35; PMID: 18322166
   PubMed Web of Science ®Google Scholar
• Fleming MD, Bear HD, Lipshy K, Kostuchenko PJ, Portocarero D, McFadden AW, et al. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro. J Immunother Emphasis Tumor Immunol 1995; 18:147 - 55; PMID: 8770770
   PubMed Web of Science ®Google Scholar
• Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, et al. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Int Immunol 2004; 16:1283 - 94; http://dx.doi.org/10.1093/intimm/dxh130; PMID: 15262898
   PubMed Web of Science ®Google Scholar
• Ariza ME, Ramakrishnan R, Singh NP, Chauhan A, Nagarkatti PS, Nagarkatti M. Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. J Biol Chem 2011; 286:24 - 34; http://dx.doi.org/10.1074/jbc.M110.135921; PMID: 21036898
   PubMed Web of Science ®Google Scholar
• Garcia CS, Curiel RE, Mwatibo JM, Pestka S, Li H, Espinoza-Delgado I. The antineoplastic agent bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells: transcriptional and posttranscriptional control of IFN-gamma R2. J Immunol 2006; 177:2707 - 16; PMID: 16888033
   PubMed Web of Science ®Google Scholar
• Li H, Wojciechowski W, Dell'Agnola C, Lopez NE, Espinoza-Delgado I. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways. J Immunol 2006; 177:3554 - 63; PMID: 16951314
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313 - 9; http://dx.doi.org/10.1097/01.cji.0000210386.55951.c2; PMID: 16699374
   PubMed Web of Science ®Google Scholar
• Crawley AM, Katz T, Parato K, Angel JB. IL-2 receptor gamma chain cytokines differentially regulate human CD8+CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis. Int Immunol 2009; 21:29 - 42; http://dx.doi.org/10.1093/intimm/dxn120; PMID: 19011158
   PubMed Web of Science ®Google Scholar
• Paiardini M, Cervasi B, Albrecht H, Muthukumar A, Dunham R, Gordon S, et al. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol 2005; 174:2900 - 9; PMID: 15728501
   PubMed Web of Science ®Google Scholar
• Berzofsky JA, Terabe M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol Immunother 2008; 57:1679 - 83; http://dx.doi.org/10.1007/s00262-008-0495-4; PMID: 18369622
   PubMed Web of Science ®Google Scholar
• Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 2004; 4:231 - 7; http://dx.doi.org/10.1038/nri1309; PMID: 15039760
   PubMed Web of Science ®Google Scholar
• Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008; 111:5637 - 45; http://dx.doi.org/10.1182/blood-2007-05-092866; PMID: 18417738
   PubMed Web of Science ®Google Scholar
• Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H, et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 2005; 11:7322 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-05-0877; PMID: 16243803
   PubMed Web of Science ®Google Scholar
• Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 2004; 114:1800 - 11; PMID: 15599405
   PubMed Web of Science ®Google Scholar
• Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, Mordoh J, et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 2005; 202:1507 - 16; http://dx.doi.org/10.1084/jem.20050956; PMID: 16330814
   PubMed Web of Science ®Google Scholar
• Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010; 123:39 - 49; http://dx.doi.org/10.1007/s10549-009-0622-8; PMID: 19898981
   PubMed Web of Science ®Google Scholar